Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ontario plans to expand newborn screening:

This article was originally published in Clinica

Executive Summary

Ontario's newborn screening programme, launched at the end of last month, will provide Can$7m (US$6m) annually to expand the number of tests available, including for several rare genetic disorders. The funds will be used to support the laboratory and to buy high-tech screening equipment. The overall Can$18m programme, announced at the end of last year (see Clinica No 1184, p 12), is unique in Canada for testing for blood disorders in newborns, such as sickle cell disease. It is expected to serve around 130,000 families each year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT051913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel